The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations
Abstract
The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, > or = 2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations > or = 200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey, the proportion of individuals with triglyceride levels Ն200 mg/dL who had achieved their non-HDL-C goal ranged from 64% with 0 to 1 risk factor to 52% with Ն2 risk factors and only 27% with CVD risk equivalents.223”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [223]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationThe Lipid Treatment Assessment Project (L-TAP)
Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012
Self-citationFord, E. S., Mokdad, A. H., Giles, W. H., & Mensah, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000066320.27195.b4 · Cited by 355
Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048061 · Cited by 196
Cited by
Sorted by citations
Items 201–268 of 268
Brudi, P., Reckless, J. P. D., Henry, D., Pomykaj, T., Lim, S. T., Massaad, R., Vandormael, K., & Johnson‐Levonas, A. O. (2008) · Cardiology · doi:10.1159/000172795 · Cited by 6
Huang, Z., Li, Q., Ye, W., Zhang, Q., & Li, X. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00685 · Cited by 6
Triglycerides and Cardiovascular Disease : A Scientific Statement From the
Pennathur, S., Kris‐Etherton, P. M., Lennie, T. A., Levi, M., Mazzone, T., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Stone, N. J., Ballantyne, C. M., et al. (2011) · Cited by 6
Self-citationFocus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia
Devito, F., Zito, A., Ricci, G., Carbonara, R., Dentamaro, I., Cortese, F., Carbonara, S., & Ciccone, M. M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.021 · Cited by 6
Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care
Hildemann, S. K., Karmann, B., Pittrow, D., Barho, C., Darius, H., & Bode, C. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802134755 · Cited by 6
Miller, M. J. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.05662.x · Cited by 6
Low-density lipoprotein cholesterol lowering therapies
Gadi, R., & Figueredo, V. M. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000193 · Cited by 5
Advances in Lipid Testing and Management in Patients with Diabetes Mellitus
Vasudevan, M. M., & Ballantyne, C. M. (2009) · Endocrine Practice · doi:10.4158/ep09190.ra · Cited by 5
Self-citationPourrafsanjani, M. H., Shal, E. K., & Khezrpour, S. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00298-5 · Cited by 6
Weart, C. W., & Hogan, R. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.516747 · Cited by 5
Elbarasi, E. A., Goodman, S. G., Yan, R. T., Tan, M., Hackam, D. G., Leiter, L. A., Langer, A., & Yan, A. T.-K. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.06.013 · Cited by 5
Ramjeeth, A., Butkow, N., Raal, F. J., & Maholwana-Mokgatlhe, M. (2008) · Europe PMC (PubMed Central) · Cited by 5
Cardiovascular Risk Assessment and Hyperlipidemia
Becker, J. D. (2008) · Critical Care Nursing Clinics of North America · doi:10.1016/j.ccell.2008.03.014 · Cited by 5
McKenney, J. M., Gandhi, S. K., Fox, K. M., & Ohsfeldt, R. L. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.10.004 · Cited by 4
Self-citationOhsfeldt, R. L., Gandhi, S. K., & Fox, K. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902905658 · Cited by 4
Zema, M. J. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.02.008 · Cited by 4
Gómez-Marcos, M. Á., Rodríguez‐Sánchez, E., Ramos-Delgado, E., Alonso, C. F., Montejo, A. L., & García‐Ortiz, L. (2009) · Atención Primaria · doi:10.1016/j.aprim.2008.10.008 · Cited by 4
A new approach to the treatment of dyslipidemia
Kėvelaitienė, S., & Šlapikas, R. (2008) · Medicina · doi:10.3390/medicina44050053 · Cited by 4
The Combination of Ezetimibe and Statin: A New Treatment for Hypercholesterolemia
Nodari, S., Rocca, P., Saporetti, A., Bettari, L., Foresti, A. L., Tanghetti, E., Metra, M., & Cas, L. D. (2007) · Heart International · doi:10.1177/1826186807003001-202 · Cited by 4
Briseño, G. G., & Mino‐León, D. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003694498 · Cited by 4
Pharmacogenetics of the response to statins
Voora, D., & Ginsburg, G. S. (2009) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-009-0064-1 · Cited by 4
DEEDWANIA, P. C., Maki, K. C., Dicklin, M. R., Stone, N. J., Ballantyne, C. M., & Davidson, M. H. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2006.05902.x · Cited by 4
Self-citationToth, P. P. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.067 · Cited by 3
Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy.
Lynch, J. T., Cooke, C. E., Rosen, J. D., Gandhi, S. K., & Bullano, M. F. (2010) · Europe PMC (PubMed Central) · Cited by 3
Lipid Management in High Risk Coronary Patients: How Effective are We at Secondary Intervention?
Zhu, Y. Y., Hayward, P. A., Hare, D. L., Stewart, A. G. O., & Buxton, B. F. (2011) · Heart Lung and Circulation · doi:10.1016/j.hlc.2011.10.013 · Cited by 3
Combination Therapy for Dyslipidemia
Davidson, D., Wilkinson, M. J., & Davidson, M. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00027-x · Cited by 3
Self-citationCrouse, J. R., Elam, M. B., Robinson, J. G., Ambrosius, W. T., & Ginsberg, H. N. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.060 · Cited by 3
Factors Associated with Lipid Goal Attainment among Patients with Deployed Drug Eluting Stent.
Su, M., Tsai, C., Yeh, H., & Chen, C. (2014) · Europe PMC (PubMed Central) · Cited by 2
Current concerns and difficulties in the prevention of cardiovascular diseases.
Rallidis, L. S., & ANASTASIOU‐NANA, M. I. (2011) · PubMed · Cited by 2
Combination Therapy for Dyslipidemia
Davidson, M. H. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50033-0 · Cited by 2
Self-citationPrevalence of Elevated Non-HDL Cholesterol among Patients with Diabetes in An Iranian Population
Kheirollahi, A., & Karkhaneh, A. (2020) · International Journal of Medical Laboratory · doi:10.18502/ijml.v7i2.2909 · Cited by 2
Farnesoid X receptor as a therapeutic target for dyslipidemia
Evans, M. J., & Gardell, S. J. (2009) · Clinical Lipidology · doi:10.2217/clp.09.51 · Cited by 2
Statin Drug Interactions in Patients with Comorbidities and on Multiple Medications
Ito, M. K. (2012) · US Endocrinology · doi:10.17925/use.2012.08.02.104 · Cited by 2
Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia
Toth, P. P., Nikolić, D., Rizz, M., Rysz, J., & Banach, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_1 · Cited by 2
Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population
Song, J., Wang, C. C., Huang, Y., Sanchez, J., Nguyen, T. H.-A., Khan, S., Kim, M., & Li, P. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060106 · Cited by 2
Pharmacological Therapy for Cardiovascular Disease
Davidson, M. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_7 · Cited by 2
Self-citationDänschel, W., Steinhagen‐Thiessen, E., Buffleben, C., Pittrow, D., & Hildemann, S. K. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.750602 · Cited by 1
The Role of Omega-3 Fatty Acids in Dyslipidemias
Brandt, E. J., & Davidson, M. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_5 · Cited by 1
Self-citationNon-HDL Cholesterol: When—and How—to Treat
Shahady, E. J. (2008) · The consultant · Cited by 1
Other Possible Drug Combinations for Dyslipidemia
Kostner, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_10 · Cited by 1
Han, H.-R., Choi, J. H., Yoo, J. H., Jeong, J.-H., Na, S.-B., Kang, J., Kim, D.-W., & Park, C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111374 · Cited by 1
Kim, J., Kim, E.-J., Kim, J.-H., & Oh, C.-O. (2015) · Korean Journal of Family Practice · Cited by 1
Low-Density Lipoprotein Cholesterol
Davidson, M. H., & Toth, P. P. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00014-7 · Cited by 1
Self-citationIs it time to reassess the approach to statin therapy?
Shah, B. R., & Ng, D. S. (2006) · Global Heart · doi:10.1016/j.precon.2006.06.008
Non-drug Intervention in Lipid Management: Dietary Portfolio
Kim, I. J. (2007) · The Journal of Korean Diabetes Association · doi:10.4093/jkda.2007.31.5.377
Increasing lipid adherence to goal
Davidson, E., Uhlenhake, E. E., & McCord, G. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.010
Ezetimibe – An Overview of its Low-density Lipoprotein Cholesterol Lowering Efficacy
Τζιόμαλος, Κ., & Mikhailidis, D. P. (2007) · European Cardiology Review · doi:10.15420/ecr.2007.0.1.23
Lipid management in clinical practice
Jialal, I., & Devaraj, S. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd547
Alternate Approaches To Managing Lipid-Associated Cardiovascular Risk
Hsia, S. H. (2007) · Future Lipidology · doi:10.2217/17460875.2.2.157
Clinical lipid management of patients with mild-to-moderate hypertriglyceridemia
Maki, K. C., Dicklin, M. R., & Bays, H. E. (2012) · Clinical Lipidology · doi:10.2217/clp.12.37
Self-citationProgress report: EMR-based cholesterol management
Aspry, K. E., & Campbell, J. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.12.006
Primary prevention of coronary artery disease in patients with type 2 diabetes mellitus
Harrall, J. M., & Tufo, A. (2012)
Role of statin therapy in the management of patients with the metabolic syndrome
Dembowski, E., & Davidson, M. H. (2007) · Archives of Medical Science
Self-citationCardiovascular Disease in Racial/Ethnic Minorities: Overview and Perspectives
Ferdinand, K. C., & Armani, A. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-410-0_1
Cardiovascular Benefits of Aggressive Cholesterol-Lowering Therapy
Clearfield, M. B. (2011) · The Journal of the American Osteopathic Association
Reckless, J. P. D., Henry, P., Pomykaj, T., Lim, S., Massaad, R., Vandormael, K., Johnson‐Levonas, A. O., Lis, K., Brudi, P., & Allen, C. (2009) · Via Medica Journals
Ito, M. K., McKenney, J. M., & Brinton, E. A. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.s1-c.1
Self-citationTriglycerides and Cardiovascular Disease: A Scientific Statement From the American
Lennie, T. A., Levi, M., Mazzone, T., Pennathur, S., Goldberg, A. C., Howard, W. J., Jacobson, M. Z., Stone, N. J., Ballantyne, C. M., Bittner, V., et al. (2013)
Self-citationManagement of Elevated Low-Density Lipoprotein Cholesterol
Davidson, M. H., & Robinson, J. G. (2013) · CRC Press eBooks · doi:10.3109/9781420019667-13
Self-citationTherapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides
Davidson, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00025-4
Self-citationOrganizing Services for Organizing Services for Cardiovascular Prevention Cardiovascular Prevention
Block, R., & Pearson, T. A. (2007)
Self-citationPharmacologic Therapy for Hypertriglyceridemia and Low HDL: Rationale for Combination Therapy
Davidson, M. H. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50032-2
Self-citation(2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277985.25720.16
Management of Elevated Low-Density Lipoprotein Cholesterol
Davidson, M. H., & Robinson, J. G. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.007
Self-citationHoussay, S., Martín, C. G., Arinovich, B., González, E. L., Sabán, M., & Schraier, S. (2022) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v56i2sup.537
Davidson, D., & Davidson, M. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3694-2_14
Self-citation
Metadata
- Authors
- Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., & Ballantyne, C. M.
- Affiliations
- University of Rochester Medicine (US)
- Massachusetts General Hospital (US)
- National Clinical Research (US)
- University of California, Los Angeles (US)
- Vanderbilt University (US)
- SUNY Downstate Health Sciences University (US)
- Baylor College of Medicine (US)
- Corresponding author
- Davidson, Michael H.
- ORCID
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 96
- Issue
- 4
- Pages
- 556-563
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W1969054950
- Cited by
- 270
- References
- 6
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 12 · 2014: 15 · 2013: 16 · 2012: 19
- FWCI
- 28.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- National Cholesterol Education Program, Adult Treatment Panel III, non-HDL cholesterol, cardiovascular risk stratification, very high-risk patients, coronary artery disease, diabetes mellitus, treatment gap, lipid control, aggressive lipid-lowering therapy
- MeSH terms
- Anticholesteremic Agents, Cholesterol, Coronary Artery Disease, Female, Follow-Up Studies, Health Surveys, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Medical Laboratory Science, Hypertriglyceridemia, Program Evaluation, Treatment Outcome, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
